Adefovir-d4 (Synonyms: PMEA-d4) |
Catalog No.GC46805
One-Click Copy Product Info
|
An internal standard for the quantification of adefovir
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1190021-70-5
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Adefovir-d4 is intended for use as an internal standard for the quantification of adefovir by GC- or LC-MS. Adefovir is an active metabolite of the antiviral nucleoside analog adefovir dipivoxil .1 Adefovir is formed from adefovir dipivoxil by gastrointestinal carboxylesterase 2 (CES2).2 It inhibits cytopathogenicity induced by herpes simplex virus 1 (HSV-1) and HSV-2 (EC50 = 7 µg/ml for both in E6SM cells), HIV-1 and HIV-2 (EC50s = 1.8 and 2.5 µg/ml, respectively, in CEM cells), and varicella zoster virus (VZV; EC50 = 10 µg/ml in human embryonic lung fibroblasts).3 Adefovir (50 mg/kg, p.o.) reduces increases in lymph node viral DNA and serum IgG levels in a mouse model of AIDS induced by infection with the retroviral complex LP-BM5.4 It also inhibits tumor growth induced by Moloney sarcoma virus (MSV) infection in mice at the same dose.5
1.Arimilli, M.N., Dougherty, J.P., Cundy, K.C., et al.Orally bioavailable acyclic nucleoside phosphonate prodrugs: Adefovir dipivoxil and bis(POC)PMPAAdvances in Antiviral Drug Design369-91(1999) 2.Laizure, S.C., Herring, V., Hu, Z., et al.The role of human carboxylesterases in drug metabolism: Have we overlooked their importance•Pharmacotherapy33(2)210-222(2013) 3.HolÝ, A., Votruba, I., MasojÍdkovÁ, M., et al.6-[2-(Phosphonomethoxy)alkoxy]pyrimidines with antiviral activityJ. Med. Chem.45(9)1918-1929(2002) 4.Rossi, L., Dominici, S., Serafini, S., et al.Pharmacokinetic and antiretroviral activity in mice of oral [P1,P2-bis[2-(adenin-9-yl)ethoxymethyl]phosphonate], a prodrug of 9-(2-phosphonylmethoxyethyl)adenineJ. Antimicrob. Chemother.50(3)365-374(2002) 5.Naesens, L., Balzarini, J., Bischofberger, N., et al.Antiretroviral activity and pharmacokinetics in mice of oral bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine, the bis(pivaloyloxymethyl) ester prodrug of 9-(2-phosphonylmethoxyethyl)adenineAntimicrob. Agents Chemother.40(1)22-28(1996)
| Cas No. | 1190021-70-5 | SDF | |
| Synonymes | PMEA-d4 | ||
| Canonical SMILES | [2H]C([2H])(N1C=NC2=C(N)N=CN=C21)C([2H])([2H])OCP(O)(O)=O | ||
| Formula | C8H8D4N5O4P | M.Wt | 277.2 |
| Solubility | DMSO: soluble | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.6075 mL | 18.0375 mL | 36.075 mL |
| 5 mM | 721.5 μL | 3.6075 mL | 7.215 mL |
| 10 mM | 360.8 μL | 1.8038 mL | 3.6075 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 34 reference(s) in Google Scholar.)